Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer
2024

MCL-1S in Cancer: A New Therapeutic Target

publication 10 minutes Evidence: moderate

Author Information

Author(s): Hartman Mariusz L.

Primary Institution: Medical University of Lodz

Hypothesis

Can alternative splicing of MCL-1 pre-mRNA provide a new therapeutic approach in cancer treatment?

Conclusion

The study suggests that increasing levels of the pro-apoptotic MCL-1S isoform may enhance cancer cell sensitivity to treatment.

Supporting Evidence

  • MCL-1S is generated through alternative splicing, specifically via exon skipping.
  • MCL-1S acts as a pro-apoptotic protein by binding exclusively to MCL-1L.
  • Upregulating MCL-1S by interfering with splicing machinery induces apoptosis in cancer.

Takeaway

MCL-1S is a special protein that helps cancer cells die, and scientists think we can use it to make cancer treatments work better.

Methodology

This review discusses the structure and function of MCL-1S and its potential therapeutic inducers based on existing literature.

Limitations

The review primarily synthesizes existing studies and does not present new experimental data.

Digital Object Identifier (DOI)

10.1038/s41419-024-07307-z

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication